EP2068885B1 - Vitamin d compositions and method of administration to a human being - Google Patents
Vitamin d compositions and method of administration to a human being Download PDFInfo
- Publication number
- EP2068885B1 EP2068885B1 EP07719767.1A EP07719767A EP2068885B1 EP 2068885 B1 EP2068885 B1 EP 2068885B1 EP 07719767 A EP07719767 A EP 07719767A EP 2068885 B1 EP2068885 B1 EP 2068885B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- composition
- infant
- pacifier
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940046008 vitamin d Drugs 0.000 title claims description 124
- 239000000203 mixture Substances 0.000 title claims description 38
- 241000282414 Homo sapiens Species 0.000 title claims description 19
- 238000000034 method Methods 0.000 title description 25
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 134
- 229930003316 Vitamin D Natural products 0.000 claims description 123
- 235000019166 vitamin D Nutrition 0.000 claims description 123
- 239000011710 vitamin D Substances 0.000 claims description 123
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 121
- 210000002445 nipple Anatomy 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 17
- 239000011647 vitamin D3 Substances 0.000 claims description 17
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 235000005282 vitamin D3 Nutrition 0.000 claims description 12
- 229940021056 vitamin d3 Drugs 0.000 claims description 12
- 230000009469 supplementation Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229940057917 medium chain triglycerides Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 4
- 235000021318 Calcifediol Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000007442 rickets Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 4
- 239000011653 vitamin D2 Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 235000019195 vitamin supplement Nutrition 0.000 description 3
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- -1 unsaturated fatty-acid triglycerides Chemical class 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 240000003133 Elaeis guineensis Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to compositions comprising vitamin D in a medium-chain triglyceride medium and use thereof for human beings, particularly, breast-feeding infants.
- Vitamin D appears to increase the efficiency of the intestines to absorb calcium and also mobilizes calcium from bone tissue when required.
- a deficiency in vitamin D leads to rickets, a debilitating bone disease while excessive intakes of vitamin D are toxic.
- the skin is the major site of cholesterol production and humans acquire vitamin D through the natural action of ultraviolet light on the skin.
- 7-Dehydrocholesterol which is unstable to ultraviolet light, is normally a precursor to cholesterol.
- ultraviolet light breaks open the B-ring of the 7-dehydrocholesterol molecule to generate previtamin D3, which spontaneously isomerizes over hours and days into vitamin D3, which is also known as cholecalciferol.
- An unknown proportion of the vitamin D from the skin is absorbed into the circulation.
- Vitamin D3 is not soluble in water, and in the circulation, there is a protein that specifically binds to and carries vitamin D and its metabolites.
- the advantage of ultraviolet exposure is that it is natural, and has no vitamin D toxicity associated with it.
- the disadvantage is that the availability of ultraviolet light is unreliable, and too much of it causes sunburn or skin cancer. At northern latitudes there is often not enough ultraviolet light intensity outdoors to generate previtamin D.
- Vitamin D For biological activity, vitamin D must go through two metabolic steps. Vitamin D is metabolized by the liver to 25-hydroxyvitamin D [25(OH)D], which is measured in serum to reflect vitamin D nutritional status. 25-hydroxyvitamin D per se has little biological activity. The kidney metabolizes 25-hydroxyvitamin D into the active hormone, 1, 25-dihydroxyvitamin D, which affects calcium transport across cell membranes. The body, according to its mineral requirements, carefully regulates production and breakdown of 1,25-dihydroxyvitamin D to regulate plasma calcium concentrations. Very few foods naturally contain vitamin D.
- vitamin D a natural supplement, cod-liver oil, contained an agent that prevented rickets; the agent became known as vitamin D.
- Most of the vitamin D in our food is supplementary, synthetic material, which is either in the form of vitamin D3, the form naturally produced in animals, or it can be vitamin D2, which is derived from a plant steroid.
- the term, vitamin D refers to either the vitamin D2 or vitamin D3 forms.
- Vitamin D liquid drops usually contain other vitamins as well.
- One milliliter of these products contains 400 IU (10 mcg) of vitamin D.
- the aqueous vitamin D drops have only a 50-day shelf-life once the bottle is opened. They contain ingredients foreign to infant nutrition, and there are many complaints about the taste.
- One major problem is that infants spit out the 1 mL liquid vitamin drops. This creates a mess and the dose delivered to the infant is unreliable.
- inconvenience, risk, and difficulty with administration result in lower compliance rates. Poor compliance results in under-dosing, and ineffective treatment. These factors also diminish nutrient supplementation with vitamin D.
- vitamin D drops available in oil, at 400 IU per drop in the United States (naturalhealthsupply.com).
- the vitamin D for this is dissolved in olive oil and/or corn oil and/or sesame or flax-seed oil.
- the problem with these is that the oils are comprised of long-chain unsaturated fatty-acid triglycerides that will become rancid with repeated opening of the container, they carry a flavor, and they have a greasy feel on a pacifier.
- no product like this is advised for, nor advocated, nor used in any way for nutrition of the breastfeeding infant.
- One prescription product contains vitamin D in an unspecified oil, (20,000 IU (500 meg) per mL of oil).
- the method for use involves mixing two drops into to two drops in milk or mash. This is not a practical way to provide vitamin D for breast-fed infants younger than two months of age, because it presumes that nutrition is provided by some means other than the breast. Furthermore, this method is no different from what is done in North America with the 1 -mL per day liquid vitamin drops that are administered to infants by mixing into milk or food by the same method.
- vitamin D is fortified into infant formula.
- TM Similac Special Care
- Greer F.R., Steichen J.J, Tsang R.C. "Effects of increased calcium, phosphorus, and vitamin D intake on bone mineralization in very low-birth-weight infants fed formulas with Polycose and medium-chain triglycerides", The Journal of Pediatrics 1982; 100:951-955 ).
- United States Patent No. 4,248,867 issued to Ikushima et al on February 3, 1981 describes a method for manufacturing an oily preparation which comprises irradiating a triglyceride of saturated middle chain fatty acid(s) with light longer than 290 nm. This process alters the oil to be a solvent in which a selection of 1 -alpha-hydroxy-vitamin Ds in the treated triglyceride can be dissolved and remain stable.
- These 1 -hydroxy vitamin D's are either diol or triol compounds which are fundamentally different from vitamin D 2 and vitamin D 3 .
- US5620462 (Valenti ), describes a medicine dropper or dispenser in the shape of a pacifier.
- this approach utilizes liquid within a chamber which passes through a pinhole orifice when sucked, rather than providing an approach wherein a drop of a liquid is sucked off the exterior surface of a pacifier, or the like.
- vitamin D means (5Z-7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol also having the trivial names cholecalciferol or calciol (D3); and ergocalciferol (D2).
- a composition and method has been developed which involves the application of a vitamin D composition to a human being from the surface of an object that is a suitable and efficient method of administration of a desired amount of vitamin D to the human being.
- the human being may be an adult or an infant.
- infant in this specification includes babies and small children, and the term “adult” includes non-small children.
- the method comprises the application of, preferably, one drop of a solution of vitamin D in a suitable, biologically-acceptable oil carrier in the case of an infant onto a mother's nipple or onto a pacifier, and placing it into the mouth of an infant for, preferably, at least 30 seconds, to suck the vitamin D composition off the nipple or pacifier, to thereby consume the vitamin D.
- one or more drops may be applied to the skin of an arm or a knuckle of the hand of the adult who then licks or sucks the composition from the skin.
- the process of the present invention can improve compliance by parents to government and medical recommendations to supplement their infants with vitamin D.
- Implementation of the invention to improve vitamin D supplementation may lower risk of disease for the infant, which, on a broader scale, should benefit public health.
- compositions for use as a medicament for vitamin D supplementation by providing a nutritional or therapeutic effective amount of vitamin D in a human being, which composition consists of vitamin D at a level of 150-450 mcg/ml, in a liquid triglyceride of 6 to 12 carbon chain length medium, wherein said composition is applied to an object surface, and having said human being suck said composition from said object surface.
- the medium chain triglycerides of use in the practice of the invention have carbon-chain lengths of 6 - 12 and, preferably, the composition medium comprises at least 95% triglycerides having a carbon-chain length selected from 8 - 10.
- Medium-chain triglycerides are obtained from the oil extracted from the hard, dried fraction of the endosperm of Cocos nucifera L. or from the dried endosperm of Elaeis guineensis Jacq. They consist of a mixture of triglycerides of saturated fatty acids, mainly of caprylic acid (C 8 H 16 O 2 ) and of capric acid (C IO H 20 0 2 ). They contain not less than 95 percent of saturated fatty acids having 8 to 10 carbon atoms. The substance is a clear solution.
- the invention provides a composition as hereinabove defined for use in delivering a nutritional or therapeutic amount of said vitamin D directly into the mouth of an infant from the surface of an object having said composition on said surface to be sucked from said surface by said infant.
- Fatty acid composition The fatty acid fraction of medium-chain triglycerides exhibits the following composition, as determined in the section Fatty Acid Composition. Any peak with an area less than 0.05% of the total area, was disregarded. Carbon-Chain Length Number of Double Bonds Percentage (%) 6 0 ⁇ 2.0 8 0 50.0 - 8.0 10 0 20.0 - 50.0 12 0 ⁇ 3.0 14 0 ⁇ 1.0
- the invention provides use of a composition as hereinabove defined for the use in delivering a nutritional or therapeutic amount of vitamin D directly from the surface of an object having the composition thereon to be licked or sucked therefrom by a human being, particularly, an infant.
- the invention provides a method of using a composition as hereinabove defined comprising (i) applying said composition to a surface of an object; and (ii) inserting said object into the mouth of an infant as to allow said infant to suck said composition from said object surface.
- the object is a woman's nipple or a pacifier
- the medium-chain triglycerides of use in this invention are liquids that are sufficiently viscous so that one drop does not immediately drip or roll away from the part of the nipple or pacifier that enters the mouth of an infant.
- the liquid does not coat or adhere to the pacifier so as to prevent efficient removal of the vitamin D from the nipple or pacifier through sucking.
- the liquid has minimal sensory effects i.e. it has minimal smell, taste, or texture i.e. no oily feel.
- the liquid is biologically natural in the context of breast-feeding, and is safe for infant consumption.
- the liquid per se is not subject to rancidity or oxidation over the shelf-life of the composition. Further, it is a medium in which vitamin D does not degrade and, thus, allows of a long shelf life for vitamin D.
- This experiment was to determine the efficacy of the uptake of vitamin D in the composition and method through the mouth by sucking and into the body.
- vitamin D in a solution of medium-chain triglyceride was applied, as a compative exampleto pacifiers.
- One drop of an approximate volume of 33 microliters was applied onto pacifiers, Gerber NukTM sizes 1 (small, for newborns) and 3 (for older infants).
- 33 microliters of vitamin D in medium- chain triglyceride (60,000 IU/33 microliters) was added to 50 mL ethanol directly, or placed onto a pacifier, which was placed in ethanol.
- pacifiers were sucked by humans for 30 seconds, and the pacifier was then placed entirely into an 80-mL beaker containing 50 mL ethanol to extract remaining vitamin D. It is important to note that the extraction of remaining vitamin D from the pacifier into ethanol was not immediate. The pacifiers were extracted for 30 min, otherwise measurement of the remaining vitamin D would have been underestimated, with overestimation of efficiency of delivery into the mouth. High-pressure liquid chromatography with absorbance detection at 265 nm of 100 microliters of the ethanol extracts from each of seven such experiments showed that vitamin D remaining on the pacifier comprised a mean of 4% +/- 2%SD of the vitamin D applied to the pacifier.
- Vitamin D 3 was added to medium-chain triglyceride oil to a concentration of 0.4 g per 10 mL. One drop of this had a volume of 33 microliter, and contained 1500 mcg of vitamin D 3 . This is a relatively high dose which was used to elicit a rapid 25(OH)D response that could not be attributed to other factors.
- Crystalline vitamin D 3 (cholecalciferol, United States Pharmacopea grade) was dissolved into oil of medium chain triglyceride (United States Pharmacopea grade), to make a solution, according to the invention, containing 300 mcg vitamin D per one mL of oil.
- This composition was bottled in a glass container closed with a Eurodropper cap, with an opening designed to dispense 30 drops per one mL of oil.
- a breast-feeding mother applied one drop of the solution to the nipple just before offering her breast to her infant to suckle. To ensure complete delivery of the dose, the infant sucked for 30 seconds.
- Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into an oil of medium chain triglycerides (United States Pharmacopea grade), to make a solution containing 300 mcg vitamin D per one mL of oil. This was bottled in a glass container closed with a Eurodropper cap, with an opening designed to dispense 30 drops per one mL of oil. The human being applied one drop of the solution to a knuckle of a hand from which the vitamin D was sucked into the mouth. To ensure complete delivery of the dose, the human sucked for 30 seconds.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
- This invention relates to compositions comprising vitamin D in a medium-chain triglyceride medium and use thereof for human beings, particularly, breast-feeding infants.
- A balanced level of vitamin D has long been recognized as essential to health. Vitamin D appears to increase the efficiency of the intestines to absorb calcium and also mobilizes calcium from bone tissue when required. A deficiency in vitamin D leads to rickets, a debilitating bone disease while excessive intakes of vitamin D are toxic.
- The skin is the major site of cholesterol production and humans acquire vitamin D through the natural action of ultraviolet light on the skin. 7-Dehydrocholesterol, which is unstable to ultraviolet light, is normally a precursor to cholesterol. However, ultraviolet light breaks open the B-ring of the 7-dehydrocholesterol molecule to generate previtamin D3, which spontaneously isomerizes over hours and days into vitamin D3, which is also known as cholecalciferol. An unknown proportion of the vitamin D from the skin is absorbed into the circulation. Vitamin D3 is not soluble in water, and in the circulation, there is a protein that specifically binds to and carries vitamin D and its metabolites. The advantage of ultraviolet exposure is that it is natural, and has no vitamin D toxicity associated with it. The disadvantage is that the availability of ultraviolet light is unreliable, and too much of it causes sunburn or skin cancer. At northern latitudes there is often not enough ultraviolet light intensity outdoors to generate previtamin D.
- For biological activity, vitamin D must go through two metabolic steps. Vitamin D is metabolized by the liver to 25-hydroxyvitamin D [25(OH)D], which is measured in serum to reflect vitamin D nutritional status. 25-hydroxyvitamin D per se has little biological activity. The kidney metabolizes 25-hydroxyvitamin D into the active hormone, 1, 25-dihydroxyvitamin D, which affects calcium transport across cell membranes. The body, according to its mineral requirements, carefully regulates production and breakdown of 1,25-dihydroxyvitamin D to regulate plasma calcium concentrations. Very few foods naturally contain vitamin D. Mellanby, J Physiol (London) volume 52:liii (1919), instituted the idea that an artificial supplement, cod-liver oil, contained an agent that prevented rickets; the agent became known as vitamin D. Most of the vitamin D in our food is supplementary, synthetic material, which is either in the form of vitamin D3, the form naturally produced in animals, or it can be vitamin D2, which is derived from a plant steroid. The term, vitamin D, refers to either the vitamin D2 or vitamin D3 forms.
- Pediatric associations in Canada and the United States now strongly encourage starting vitamin D supplementation from birth onwards (Health Canada, Vitamin D supplementation for breastfed infants). Breast-feeding results in fewer infections and allergies during the first year of life compared to babies fed formula. Breast milk provides nearly optimal nutrition for newborns; however, it provides little vitamin D. Vitamin D has well-recognized effects on bone, but beyond that, better vitamin D nutrition during infancy is associated with less risk of other diseases that develop later in life. These disease reductions include less risk of juvenile diabetes, and schizophrenia (Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R., and Virtanen, S. M. (2001) Lancet 358, 1500-1503) (McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Jarvelin, M. R., Chant, D., and Isohanni, M. (2004) Schizophr. Res. 67, 237-245). However, because it is normally obtained through sun exposure instead of orally, vitamin D is the one nutrient that is most often deficient in breast milk (Centers for Disease Control, Vitamin D Expert Panel Meeting, October 11 - 12, 2001 Atlanta, Georgia Final Report).
- In 2005, the American Academy of Pediatrics issued a new policy statement concerning breast-feeding (American Academy Of Pediatrics Policy Statement 2005; Pediatrics 115;496-506). One major change was that all breast-fed infants should receive 200 IU (5 mcg) of oral vitamin D drops daily, beginning during the first 2 months of life. The older recommendation had been that vitamin D supplementation should start at around 2 months of life. The latest American Academy of Pediatrics recommendation follows what Health Canada has been advising, that vitamin D supplementation should be from birth, with 400 IU (10 mcg) of vitamin D per day (Pediatrics 2005;115;496-506). Moreover, Health Canada recommends that infants in the north be given 800 IU (20 mcg) of vitamin D per day.
- The need to provide vitamin D at an earlier age makes the problem of providing vitamin D nutrition more complicated. Smaller infants are more difficult to handle. Furthermore, breast-feeding mothers may not want to give their infants foreign liquids or compounds that are not natural for them to be taking. What makes the problem worse, is that the recommendations from pediatric societies and government bodies provide no detail or any method for exactly how to give vitamin D to the breast-feeding infant. They simply advise that parents should be giving vitamin D.
- Existing products, approved in Canada and the United States for the purpose of infant vitamin D nutrition require the use of one-half to one mL of a detergent-solublized aqueous liquid emulsion. The liquid is either given directly into the mouth, or mixed into milk or to other food consumed by the infant. Instructions for administering vitamin D drops typically involve inserting the dropper containing the liquid product directly into the baby's mouth.
- Parents of infants express great frustration about existing products and methods for providing infants with vitamin D, especially about the taste and the fact that infants often spit out at least some of the liquid. Direct administration of liquid vitamin D preparations is commonly done with an eyedropper, and with the infant lying on its back. One risk associated with direct administration of vitamin D solutions into the mouth is that infants can gag on, or inhale some of the liquid.
- Vitamin D liquid drops usually contain other vitamins as well. One milliliter of these products contains 400 IU (10 mcg) of vitamin D. The aqueous vitamin D drops have only a 50-day shelf-life once the bottle is opened. They contain ingredients foreign to infant nutrition, and there are many complaints about the taste. One major problem is that infants spit out the 1 mL liquid vitamin drops. This creates a mess and the dose delivered to the infant is unreliable. For any therapeutic protocol, inconvenience, risk, and difficulty with administration result in lower compliance rates. Poor compliance results in under-dosing, and ineffective treatment. These factors also diminish nutrient supplementation with vitamin D.
- There are vitamin D drops available in oil, at 400 IU per drop in the United States (naturalhealthsupply.com). The vitamin D for this is dissolved in olive oil and/or corn oil and/or sesame or flax-seed oil. The problem with these is that the oils are comprised of long-chain unsaturated fatty-acid triglycerides that will become rancid with repeated opening of the container, they carry a flavor, and they have a greasy feel on a pacifier. Moreover, no product like this is advised for, nor advocated, nor used in any way for nutrition of the breastfeeding infant.
- One prescription product contains vitamin D in an unspecified oil, (20,000 IU (500 meg) per mL of oil). The method for use involves mixing two drops into to two drops in milk or mash. This is not a practical way to provide vitamin D for breast-fed infants younger than two months of age, because it presumes that nutrition is provided by some means other than the breast. Furthermore, this method is no different from what is done in North America with the 1 -mL per day liquid vitamin drops that are administered to infants by mixing into milk or food by the same method.
- More commonly, vitamin D is fortified into infant formula. For example there is described an infant formula marketed as Similac Special Care (TM), amongst whose various ingredients are included vitamin D and medium chain triglycerides, which is administered to infants by intermittent gavage or by being sucked through the hole in the nipple or teat of a baby bottle for the baby formula (Greer F.R., Steichen J.J, Tsang R.C. "Effects of increased calcium, phosphorus, and vitamin D intake on bone mineralization in very low-birth-weight infants fed formulas with Polycose and medium-chain triglycerides", The Journal of Pediatrics 1982; 100:951-955).
- United States Patent No.
5,532,229, issued July 2, 1996 to Vieth, Reinhold W. , and Canadian Patent No.2,122,431, issued October 10, 2006 to Vieth, Reinhold W. , describe a method of delivering vitamin D to the blood of a mammal by topically administering to the skin of the mammal, vitamin D in a solution. In principle, this method could be used to provide vitamin D to infants, via the skin, which is a safe and natural route of entry for this nutrient. For example, a skin lotion that contains vitamin D can be absorbed over time through the skin of the infant. For example, medium-chain triglycerides are useful as a skin lotion, and at the same time they can function as a solvent to deliver vitamin D. However, the efficacy of vitamin D delivery is problematic with this approach, because vitamin D could be wiped easily off the skin before it could be absorbed into the body. - United States Patent No.
4,248,867, issued to Ikushima et al on February 3, 1981 describes a method for manufacturing an oily preparation which comprises irradiating a triglyceride of saturated middle chain fatty acid(s) with light longer than 290 nm. This process alters the oil to be a solvent in which a selection of 1 -alpha-hydroxy-vitamin Ds in the treated triglyceride can be dissolved and remain stable. These 1 -hydroxy vitamin D's are either diol or triol compounds which are fundamentally different from vitamin D2 and vitamin D3. - United States Patent Application
2003/192093 (Chen ) likewise reviews the suitability of various preparations for 1-hydroxylated forms of vitamin D. In that document, they show that the active vitamin D compound selected was stable under controlled conditions, in many different liquid preparations, among which was included triglyceride of saturated middle chain fatty acid(s). - The Final report by Scanlon K. S., of a Vitamin D Expert Panel conference in Atlanta Georgia, USA, October 11-12, 2001, discusses the use of vitamin D for nutritional, non-therapeutic, rickets prevention. The report emphasized that because breast-milk is a poor source of vitamin D, and because physicians "thought it unethical to expose children to sunlight without sunscreen", there is a great need either for fortification (addition of vitamin D to food or infant supplement) or for supplementation (provision of a vitamin D-only preparation). The suggested dosage for rickets prevention ranged between 200-400 international units (5-10 micrograms) per day. While one suggested strategy was to place vitamin D onto a mother's nipple before breastfeeding, no additional details were provided, and no guidance was given in this, or any subsequent discussion, on any study of the validation of this approach, or the specifics of how to put this idea into practical use.
- In addition,
US5620462 (Valenti ), describes a medicine dropper or dispenser in the shape of a pacifier. However, this approach utilizes liquid within a chamber which passes through a pinhole orifice when sucked, rather than providing an approach wherein a drop of a liquid is sucked off the exterior surface of a pacifier, or the like. - Notwithstanding the above teachings of the prior art, there remains a need for a safe, convenient and efficacious method of administering nutritional or therapeutic amounts of vitamin D to a human being, particularly, a suckling infant. There is also a utility for adults to be able to deliver a dose of vitamin D effciently by sucking a vitamin supplement from a surface, instead of directly placing the supplement directly into the mouth.
- In this specification and claims, the compound "vitamin D" means (5Z-7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol also having the trivial names cholecalciferol or calciol (D3); and ergocalciferol (D2).
- It is an object of the present invention to provide an improved, suitable, safer and efficient method of providing a nutritional or therapeutic effect amount of Vitamin D to a human being, particularly, a suckling infant.
- It is a further object to provide Vitamin D compositions for use in said method.
- A composition and method has been developed which involves the application of a vitamin D composition to a human being from the surface of an object that is a suitable and efficient method of administration of a desired amount of vitamin D to the human being.
- The human being may be an adult or an infant. The term "infant" in this specification includes babies and small children, and the term "adult" includes non-small children.
- In the case of administration of the compositions according to the invention to an infant, the method comprises the application of, preferably, one drop of a solution of vitamin D in a suitable, biologically-acceptable oil carrier in the case of an infant onto a mother's nipple or onto a pacifier, and placing it into the mouth of an infant for, preferably, at least 30 seconds, to suck the vitamin D composition off the nipple or pacifier, to thereby consume the vitamin D. In the case of an adult, one or more drops may be applied to the skin of an arm or a knuckle of the hand of the adult who then licks or sucks the composition from the skin.
- We have found that the difficulties with the aforesaid previous ways of providing vitamin D to an infant can be overcome by the process of application of vitamin D in a one-drop (about 33 microliter) volume of medium-chain triglyceride oil onto a pacifier or nipple and into the mouth of a suckling infant. This process of nipple or pacifier application eliminates the need to risk over-exposure of the infant to ultraviolet light in order to acquire in vivo vitamin D. Furthermore, the process of nipple or pacifier application eliminates the need to administer vitamin D directly into the mouth with a dropper, or in a larger volume that infants commonly spit out or gag on, or have to take with food.
- The process of the present invention can improve compliance by parents to government and medical recommendations to supplement their infants with vitamin D. Implementation of the invention to improve vitamin D supplementation may lower risk of disease for the infant, which, on a broader scale, should benefit public health.
- It is highly desirable, though not an essential consideration, that the medium-chain triglyceride is a natural constituent of breast milk since such oil use does not introduce a compound foreign to breastfeeding. Furthermore, medium-chain triglycerides are naturally present in milk fat and are hydrolyzed by lipase present in the saliva of the infant. The medium-chain free fatty acids and monoglycerides released by the action of lipase in the saliva of the infant provide the additional benefit of an antimicrobial action, and play a role in resistance to infectious diseases (M. K. M. Nair 2005 J. Dairy Sci. 88:3488-3495)(CQ Sun 2002 Chemico-Biological Interactions 140: 185-198)(AC Pedersen, A Bardow, SB Jensen, B Nauntofte 2002. Oral Diseases 8:117-129).
- We have found that the inventive method of indirect application of vitamin D to a pacifier or nipple, or knuckle can provide vitamin D nutrition to a human with an efficiency of vitamin D delivery by sucking that is in the range acceptable for accuracy of a supplement product labeled dose, with about 4% loss as residual vitamin D remaining on the nipple or pacifier, compared to direct placement of vitamin D into the mouth.
- According to the present invention there is provided a composition for use as a medicament for vitamin D supplementation by providing a nutritional or therapeutic effective amount of vitamin D in a human being, which composition consists of vitamin D at a level of 150-450 mcg/ml, in a liquid triglyceride of 6 to 12 carbon chain length medium, wherein said composition is applied to an object surface, and having said human being suck said composition from said object surface.
- The composition is useful for pediatricians who could use it to provide vitamin D as a single-drop dose at each monthly neonatal visit. Thereby, the mother, herself, would not have to deal with vitamin D application.
- The medium chain triglycerides of use in the practice of the invention have carbon-chain lengths of 6 - 12 and, preferably, the composition medium comprises at least 95% triglycerides having a carbon-chain length selected from 8 - 10.
- Medium-chain triglycerides are obtained from the oil extracted from the hard, dried fraction of the endosperm of Cocos nucifera L. or from the dried endosperm of Elaeis guineensis Jacq. They consist of a mixture of triglycerides of saturated fatty acids, mainly of caprylic acid (C8H16O2) and of capric acid (CIOH2002). They contain not less than 95 percent of saturated fatty acids having 8 to 10 carbon atoms. The substance is a clear solution.
- In a most important embodiment, the invention provides a composition as hereinabove defined for use in delivering a nutritional or therapeutic amount of said vitamin D directly into the mouth of an infant from the surface of an object having said composition on said surface to be sucked from said surface by said infant.
- Fatty acid composition - The fatty acid fraction of medium-chain triglycerides exhibits the following composition, as determined in the section Fatty Acid Composition.
Any peak with an area less than 0.05% of the total area, was disregarded.Carbon-Chain Length Number of Double Bonds Percentage (%) 6 0 ≤2.0 8 0 50.0 - 8.0 10 0 20.0 - 50.0 12 0 ≤3.0 14 0 ≤1.0 - To be useful in the practice of the present invention, the vitamin D containing medium, needs to meet many of the aforesaid criteria. Surprisingly we have discovered that the medium-chain triglycerides satisfy these criteria.
- In a further embodiment, the invention provides use of a composition as hereinabove defined for the use in delivering a nutritional or therapeutic amount of vitamin D directly from the surface of an object having the composition thereon to be licked or sucked therefrom by a human being, particularly, an infant.
- In a particular embodiment, the invention provides a method of using a composition as hereinabove defined comprising (i) applying said composition to a surface of an object; and (ii) inserting said object into the mouth of an infant as to allow said infant to suck said composition from said object surface.
- Most preferably, in the case of an infant, the object is a woman's nipple or a pacifier
- In order that the invention may be better understood, preferred embodiments will now be described by way of example only.
- The medium-chain triglycerides of use in this invention are liquids that are sufficiently viscous so that one drop does not immediately drip or roll away from the part of the nipple or pacifier that enters the mouth of an infant. The liquid does not coat or adhere to the pacifier so as to prevent efficient removal of the vitamin D from the nipple or pacifier through sucking. The liquid has minimal sensory effects i.e. it has minimal smell, taste, or texture i.e. no oily feel. The liquid is biologically natural in the context of breast-feeding, and is safe for infant consumption. The liquid per se is not subject to rancidity or oxidation over the shelf-life of the composition. Further, it is a medium in which vitamin D does not degrade and, thus, allows of a long shelf life for vitamin D.
- This experiment involved the study of a number of liquids to determine their efficiency in the practice of the invention.
- One drop of each liquid was applied onto a nipple to determine whether it would adhere well enough so that no portion of it would drip off in a timeframe of 10 seconds. The results of these experimental observations are presented in Table 1 along with further considerations regarding the parameters desired for this invention.
TABLE 1 Table 1 Experimental observation of potential liquids for suitability for nipple vitamin D Vehicle for vitamin D Experiment drop behavior on nipple# Taste# mouthfeel# taste# Stability of vitamin D in vehicle Stability of solvent with storage# present in breast milk Water drips off None none none Poor# Stable Yes Water based emulsion (D-vi-sol) drips off Yes no feel strong taste 50-days on opening* Stable No Ethanol drips off Yes no feel strong taste Solvent concentration# Evaporates No Canola oil Adheres Mild Oily mild Stable Oxidizes/ rancidity No Olive oil Adheres Yes Oily mild Stable Oxidizes/ rancidity No Sesame oil Adheres Yes Oily strong taste Stable Oxidizes/ rancidity no Vitamin E acetate oil Adheres None Oily none Uncertain Stable no Medium-chain triglyceride Adheres None slightly oily none Stable>3yr# Stable yes # Direct experimental observation.
*Mead-Johnson published stability statement for D-vi-sol. - Water based preparations and alcohol did not adhere to the nipple. The oil vehicles all adhered to the nipple well enough to make them suitable for handling during breastfeeding or for use of a pacifier. However, residual oily feel on the pacifier was interpreted as a sign of incomplete uptake of the drop with its dose from the pacifier. We found that medium-chain triglyceride oil was particularly desirable.
- This experiment was to determine the efficacy of the uptake of vitamin D in the composition and method through the mouth by sucking and into the body.
- A further problem that needed to be addressed was the matter of whether vitamin D dissolved in a liquid vehicle would be removed by sucking and enter the body of the human in an efficacious manner. For this, vitamin D in a solution of medium-chain triglyceride was applied, as a compative exampleto pacifiers. One drop of an approximate volume of 33 microliters was applied onto pacifiers, Gerber Nuk™ sizes 1 (small, for newborns) and 3 (for older infants). As the measure of 100% recovery, 33 microliters of vitamin D in medium- chain triglyceride (60,000 IU/33 microliters) was added to 50 mL ethanol directly, or placed onto a pacifier, which was placed in ethanol. To estimate efficiency of removal of the vitamin D, pacifiers were sucked by humans for 30 seconds, and the pacifier was then placed entirely into an 80-mL beaker containing 50 mL ethanol to extract remaining vitamin D. It is important to note that the extraction of remaining vitamin D from the pacifier into ethanol was not immediate. The pacifiers were extracted for 30 min, otherwise measurement of the remaining vitamin D would have been underestimated, with overestimation of efficiency of delivery into the mouth. High-pressure liquid chromatography with absorbance detection at 265 nm of 100 microliters of the ethanol extracts from each of seven such experiments showed that vitamin D remaining on the pacifier comprised a mean of 4% +/- 2%SD of the vitamin D applied to the pacifier. Therefore, delivery of the vitamin D applied to a pacifier or to a nipple and taken up into the mouth within half a minute is sufficiently reproducible and complete so as to permit a dose printed on the label of a vitamin supplement product to be claimed as being accurate. Government regulations mandate that vitamin supplements for humans must provide between 90% and 120% of the labeled doses. The dosage loss with the method according to the invention, is accommodated inside that acceptable range, so that the dose that the label states to be present in one drop of product is an appropriate measure of the dose delivered into a human.
- This comparative experiment shows that if the invention truly functioned as intended, the serum 25-hydroxyvitamin D [25(OH)D] should increase in response to the intake of vitamin D.
- Vitamin D3 was added to medium-chain triglyceride oil to a concentration of 0.4 g per 10 mL. One drop of this had a volume of 33 microliter, and contained 1500 mcg of vitamin D3. This is a relatively high dose which was used to elicit a rapid 25(OH)D response that could not be attributed to other factors. Three humans, who had not taken vitamin D supplements during the previous month each sucked on a pacifier for 30 sec, Gerber Nuk™ - brand pacifiers, to which one drop of the vitamin D3 solution in medium-chain triglyceride oil had been applied. Blood samples had been drawn prior to the experiment, and 48 h after taking the dose of vitamin D according to the present invention. Without vitamin D, there could have been no detectable change in serum 25(OH)D concentration in the short timeframe of 48 h. We found that the serum 25(OH)D increased in each human. In the three humans, the mean increase from baseline was 12 nmol/L (the individual increases in serum 25(OH)D were 5, 10 and 20 nmol/L). The results were consistent with the uptake of the vitamin D from the pacifier into the human body. This experiment confirmed the efficacy of the method of the present invention.
- Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into oil of medium chain triglyceride (United States Pharmacopea grade), to make a solution, according to the invention, containing 300 mcg vitamin D per one mL of oil. This composition was bottled in a glass container closed with a Eurodropper cap, with an opening designed to dispense 30 drops per one mL of oil. A breast-feeding mother applied one drop of the solution to the nipple just before offering her breast to her infant to suckle. To ensure complete delivery of the dose, the infant sucked for 30 seconds.
- Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into oil of medium chain triglyceride (United States Pharmacopea grade), to make a solution, according to the invention, containing 300 mcg vitamin D per one mL of oil. This composition was bottled in a plastic container with a dropper opening to dispense one drop of oil. A mother applied one drop of the solution to a pacifier or the nipple of a baby bottle just before putting it into the mouth of her infant to suck. To ensure complete delivery of the dose, the infant sucked for 30 seconds.
- Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into an oil of medium chain triglycerides (United States Pharmacopea grade), to make a solution containing 300 mcg vitamin D per one mL of oil. This was bottled in a glass container closed with a Eurodropper cap, with an opening designed to dispense 30 drops per one mL of oil. The human being applied one drop of the solution to a knuckle of a hand from which the vitamin D was sucked into the mouth. To ensure complete delivery of the dose, the human sucked for 30 seconds.
Claims (5)
- A composition for use as a medicament for vitamin D supplementation by providing a nutritional or therapeutic effective amount of vitamin D in a human being, which composition consists of vitamin D, at a level of from 150 to 450 mcg/ml, in a liquid triglyceride of 6 to 12 carbon chain length medium, wherein said composition is applied to an object surface, and having said human being suck said composition from said object surface.
- A composition for use as claimed in claim 1 consisting of crystalline vitamin D3 dissolved in oil of medium chain triglyceride having a carbon chain length of 6-12 to make a solution containing 300mcg vitamin D per one ml of oil.
- A composition for use as claimed in claim 1 wherein said object is a woman's nipple.
- A composition for use as claimed in claim 1 wherein said object is a pacifier.
- A composition for use as claimed in claim 2 wherein said composition is applied as a single drop to a breast feeding mother's nipple, to a pacifier or a nipple of a baby bottle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL07719767T PL2068885T3 (en) | 2006-09-14 | 2007-05-14 | Vitamin d compositions and method of administration to a human being |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002558202A CA2558202A1 (en) | 2006-09-14 | 2006-09-14 | Vitamin d compositions and method of administration to infants |
CA002578881A CA2578881C (en) | 2006-09-14 | 2007-02-16 | Vitamin d compositions and method of administration to a human being |
PCT/CA2007/000844 WO2008031188A1 (en) | 2006-09-14 | 2007-05-14 | Vitamin d compositions and method of administration to a human being |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2068885A1 EP2068885A1 (en) | 2009-06-17 |
EP2068885A4 EP2068885A4 (en) | 2012-02-29 |
EP2068885B1 true EP2068885B1 (en) | 2014-11-12 |
Family
ID=38283462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07719767.1A Active EP2068885B1 (en) | 2006-09-14 | 2007-05-14 | Vitamin d compositions and method of administration to a human being |
Country Status (16)
Country | Link |
---|---|
US (2) | US9066958B2 (en) |
EP (1) | EP2068885B1 (en) |
JP (1) | JP5624765B2 (en) |
KR (2) | KR20140097412A (en) |
CN (1) | CN101969958B (en) |
AU (1) | AU2007295888B2 (en) |
BR (1) | BRPI0716108B8 (en) |
CA (2) | CA2558202A1 (en) |
DK (1) | DK2068885T3 (en) |
ES (1) | ES2524776T3 (en) |
HK (1) | HK1154200A1 (en) |
MX (1) | MX2009001156A (en) |
NZ (2) | NZ574644A (en) |
PL (1) | PL2068885T3 (en) |
PT (1) | PT2068885E (en) |
WO (1) | WO2008031188A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169497A1 (en) | 2017-03-17 | 2018-09-20 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2558202A1 (en) * | 2006-09-14 | 2006-11-23 | Reinhold W. Vieth | Vitamin d compositions and method of administration to infants |
EP2289555A1 (en) * | 2009-08-24 | 2011-03-02 | OrgaNext Research B.V. | Method of treating frailty |
GB2475934A (en) * | 2009-12-02 | 2011-06-08 | Fit Bioceuticals Pty Ltd | Liquid composition comprising vitamin D |
CA2745267C (en) | 2011-07-05 | 2019-09-24 | Reinhold Vieth | Iron supplement composition |
US9008389B2 (en) * | 2012-09-28 | 2015-04-14 | Robert D. Williams | System and method for determining the amount of vitamin D generated by a user |
PL2950823T3 (en) * | 2013-02-01 | 2021-02-08 | Ddrops Company | Liquid menthol compositions |
EP2942050B1 (en) * | 2014-05-06 | 2022-09-07 | S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof |
CN105105149B (en) * | 2015-10-08 | 2018-05-25 | 辽宁美天佳生物科技有限公司 | A kind of solid granules for strengthening vitamin D |
WO2017115316A1 (en) | 2015-12-29 | 2017-07-06 | Noivita S.R.L.S. | Lipophilic formulations |
CN114009786B (en) * | 2021-11-22 | 2023-04-07 | 江南大学 | Nutritional oil composition for vitamin D delivery, preparation method and application |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3149037A (en) * | 1962-09-07 | 1964-09-15 | Hoffmann La Roche | Vitamin compositions |
JPS5452717A (en) | 1977-09-29 | 1979-04-25 | Chugai Pharmaceut Co Ltd | Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d |
CA1331559C (en) * | 1986-04-21 | 1994-08-23 | Jon Joseph Kabara | Antimicrobial preservative compositions and methods |
US5422127A (en) | 1992-12-21 | 1995-06-06 | Bristol-Myers Squibb Company | Nutritional compositions containing vitamin D esters |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
CA2122431C (en) | 1994-04-28 | 2006-10-10 | Reinhold W. Vieth | Topical administration of vitamin d to mammals and compositions therefor |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5620462A (en) | 1995-05-01 | 1997-04-15 | Valenti; Diane L. | Liquid vitamin and medicine dispenser for infants and toddlers |
US5601605A (en) * | 1995-08-29 | 1997-02-11 | Crowe; Dewey E. | Infant pacifier - fluid administering unit |
JP2000512649A (en) * | 1996-06-27 | 2000-09-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Sustained release sufentanil composition |
US6013665A (en) * | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
AUPP332898A0 (en) * | 1998-05-04 | 1998-05-28 | Unisearch Limited | Pharmaceutical composition |
JP4010062B2 (en) * | 1998-09-02 | 2007-11-21 | 医療法人社団青藍会 | Health food to prevent atopic dermatitis |
GB9906009D0 (en) | 1999-03-16 | 1999-05-12 | Nycomed Pharma As | Product |
IL133968A0 (en) | 2000-01-10 | 2001-04-30 | Thixo Ltd | Therapeutic oils and edible pastes containing the same |
US7090862B2 (en) | 2001-03-30 | 2006-08-15 | Abbott Laboratories | Method of improving the antioxidant status of an infant |
US7081248B2 (en) | 2001-08-03 | 2006-07-25 | Adisseo France S.A.S. | Concentrated water-dispersible vitamin compositions |
HUP0501186A2 (en) | 2001-12-03 | 2006-05-29 | Novacea | Pharmaceutical compositions comprising active vitamin d compounds |
US6793959B2 (en) * | 2002-03-18 | 2004-09-21 | Bunge Foods Corporation | Low viscosity structured lipid pan release compositions and methods |
JP2004065707A (en) * | 2002-08-08 | 2004-03-04 | Taro Kawasaki | Pacifier for baby and little children and pacifier for baby and little children containing xylitol |
WO2004110151A1 (en) * | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments |
CA2558202A1 (en) | 2006-09-14 | 2006-11-23 | Reinhold W. Vieth | Vitamin d compositions and method of administration to infants |
-
2006
- 2006-09-14 CA CA002558202A patent/CA2558202A1/en not_active Withdrawn
-
2007
- 2007-02-13 US US11/674,234 patent/US9066958B2/en active Active
- 2007-02-16 CA CA002578881A patent/CA2578881C/en active Active
- 2007-05-14 KR KR1020147016772A patent/KR20140097412A/en not_active Application Discontinuation
- 2007-05-14 PL PL07719767T patent/PL2068885T3/en unknown
- 2007-05-14 EP EP07719767.1A patent/EP2068885B1/en active Active
- 2007-05-14 ES ES07719767.1T patent/ES2524776T3/en active Active
- 2007-05-14 NZ NZ574644A patent/NZ574644A/en unknown
- 2007-05-14 JP JP2009527657A patent/JP5624765B2/en active Active
- 2007-05-14 CN CN200780033694.7A patent/CN101969958B/en active Active
- 2007-05-14 MX MX2009001156A patent/MX2009001156A/en active IP Right Grant
- 2007-05-14 NZ NZ599292A patent/NZ599292A/en unknown
- 2007-05-14 AU AU2007295888A patent/AU2007295888B2/en active Active
- 2007-05-14 KR KR1020097004010A patent/KR101437706B1/en active IP Right Grant
- 2007-05-14 BR BRPI0716108A patent/BRPI0716108B8/en active IP Right Grant
- 2007-05-14 DK DK07719767.1T patent/DK2068885T3/en active
- 2007-05-14 WO PCT/CA2007/000844 patent/WO2008031188A1/en active Application Filing
- 2007-05-14 PT PT77197671T patent/PT2068885E/en unknown
-
2011
- 2011-08-02 HK HK11108007.1A patent/HK1154200A1/en unknown
-
2015
- 2015-05-15 US US14/713,448 patent/US20150246062A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
H.L.J.MAKIN, D.A.SEAMARK, D.J.H. TRAFFORD: "Vitamin D and its metabolites in human breast milk", ARCIVES OF DISEASE IN CHILDHOOD, vol. 58, 31 December 1983 (1983-12-31), pages 750 - 753 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169497A1 (en) | 2017-03-17 | 2018-09-20 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Also Published As
Publication number | Publication date |
---|---|
WO2008031188A1 (en) | 2008-03-20 |
US9066958B2 (en) | 2015-06-30 |
JP5624765B2 (en) | 2014-11-12 |
EP2068885A1 (en) | 2009-06-17 |
ES2524776T3 (en) | 2014-12-12 |
CA2558202A1 (en) | 2006-11-23 |
BRPI0716108B8 (en) | 2021-05-25 |
PT2068885E (en) | 2014-12-09 |
MX2009001156A (en) | 2009-05-13 |
NZ599292A (en) | 2013-12-20 |
EP2068885A4 (en) | 2012-02-29 |
US20080069925A1 (en) | 2008-03-20 |
JP2010520850A (en) | 2010-06-17 |
NZ574644A (en) | 2012-04-27 |
BRPI0716108B1 (en) | 2019-09-03 |
CA2578881C (en) | 2008-11-04 |
CA2578881A1 (en) | 2007-07-18 |
KR20090050061A (en) | 2009-05-19 |
PL2068885T3 (en) | 2015-04-30 |
DK2068885T3 (en) | 2014-12-08 |
KR20140097412A (en) | 2014-08-06 |
AU2007295888B2 (en) | 2012-07-12 |
BRPI0716108A2 (en) | 2013-01-15 |
AU2007295888A1 (en) | 2008-03-20 |
KR101437706B1 (en) | 2014-09-03 |
US20150246062A1 (en) | 2015-09-03 |
CN101969958B (en) | 2015-04-08 |
HK1154200A1 (en) | 2012-04-13 |
CN101969958A (en) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2068885B1 (en) | Vitamin d compositions and method of administration to a human being | |
EP2658403B1 (en) | Nutritional product for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child | |
AU2018100110A4 (en) | Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto | |
CN1809339B (en) | Oil emulsion for postnatal hormone substitution | |
CN100500140C (en) | Dermal compositions containing coenzyme Q as active ingredient | |
JP2018019691A (en) | Iron supplement composition | |
US11576935B2 (en) | Non-winterized, standardized marine source oil products and methods of making thereof | |
WO2018169497A1 (en) | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability | |
EP2942050B1 (en) | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof | |
US20200397842A1 (en) | Plant-based compositions and methods for reducing cortisol levels | |
CN113143863A (en) | Oral solvent composition and preparation method and application thereof | |
CN107320468A (en) | Composite phospholipid liposome oral liquid and its preparation method and application | |
Reddy et al. | Drug Corner Advancements in Vitamin D3 Formulations: A Review of UNS D3 Ultra Nano 60 Thousand | |
Yadav et al. | Pharmaceutics | |
Kaur et al. | Avaleha Kalpana (medicated semisolid preparation): an synoptic overview | |
Heredia et al. | Iodine Deficiency in the PN dependent pediatric patient: A case study. | |
TR201705831A2 (en) | THE USE OF A VEGETABLE FORMULATION CONTAINING POMEGRANOUS SEED OIL TO REDUCE BLOOD FATS KNOWN AS TRIGLYCERITE | |
Linday | Adjuvant Therapy in Pediatric Patients: How To Prevent Upper Respiratory Tract Infections with Nutritional Supplements | |
JP2017536367A (en) | Phospholipid preparations for improving communication skills |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090123 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/44 20060101ALI20120113BHEP Ipc: A61K 9/00 20060101ALI20120113BHEP Ipc: A61J 17/00 20060101ALI20120113BHEP Ipc: A61J 7/00 20060101ALI20120113BHEP Ipc: A61P 3/02 20060101ALI20120113BHEP Ipc: A61K 9/08 20060101ALI20120113BHEP Ipc: A61K 47/14 20060101ALI20120113BHEP Ipc: A23D 9/007 20060101ALI20120113BHEP Ipc: A61K 31/59 20060101AFI20120113BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120131 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/44 20060101ALI20120124BHEP Ipc: A61K 9/00 20060101ALI20120124BHEP Ipc: A61J 17/00 20060101ALI20120124BHEP Ipc: A61J 7/00 20060101ALI20120124BHEP Ipc: A61P 3/02 20060101ALI20120124BHEP Ipc: A61K 9/08 20060101ALI20120124BHEP Ipc: A61K 47/14 20060101ALI20120124BHEP Ipc: A23D 9/007 20060101ALI20120124BHEP Ipc: A61K 31/59 20060101AFI20120124BHEP |
|
17Q | First examination report despatched |
Effective date: 20121213 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140425 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20140930 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 695328 Country of ref document: AT Kind code of ref document: T Effective date: 20141115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20141204 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2524776 Country of ref document: ES Kind code of ref document: T3 Effective date: 20141212 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 Ref country code: DE Ref legal event code: R096 Ref document number: 602007039223 Country of ref document: DE Effective date: 20141224 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI AND CIE SA, CH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150213 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007039223 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20150813 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150514 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602007039223 Country of ref document: DE Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070514 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240527 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20240524 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240520 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240521 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240529 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20240527 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240602 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240610 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20240521 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240527 Year of fee payment: 18 Ref country code: FI Payment date: 20240527 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20240514 Year of fee payment: 18 Ref country code: PT Payment date: 20240514 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20240527 Year of fee payment: 18 Ref country code: BE Payment date: 20240527 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240524 Year of fee payment: 18 |